Fermion is a company focusing on innovative drugs discovery by AI technology. The profit of our business is mainly based on cooperation with pharmaceutical companies during PCC and IND stages. With the participating of cloud-computing and supercomputers, our AI technology is able to discover the suitable targets, screen and model the active pharmaceutical molecules, which can improve the efficiency of R&D process and lower the risk of failure during clinical trials. Comparing to the traditional drug discovery, our process is much efficient and economic.
Fermion has achieved series A+ financing in November 2020. Investors includes Panda Capital, Tong Sheng Capital and Guangzhou Finance Holding Group etc. In December 2018, our series pre-A financing was achieved by the leading investment of the Challenjers and Panda Capital.